Open tender · Germany · Contract notice
Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Peginterferon alfa-2a (ATC-Code: L03AB11).
AOK Niedersachsen. Die Gesundheitskasse.
AOK Niedersachsen. Die Gesundheitskasse. in Germany is inviting bids for “Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Peginterferon alfa-2a (ATC-Code…”. Bids close on 27 September 2027. To qualify, bidders need at least one similar completed work and Pharmazeutischer Unternehmer status.
The work
Conclusion of a non-exclusive discount contract for the active substance Peginterferon alfa-2a (ATC-Code: L03AB11) within the period from 01.12.2025 to 30.11.2027.
- Contract must be for Peginterferon alfa-2a (ATC-Code: L03AB11).
- Contract duration is a maximum of 24 months.
- Earliest start date is 01.12.2025.
- Latest end date is 30.11.2027.
Key facts
- Contract period
- Maximum 24 months, ending no later than 30.11.2027.
- Evaluation
- Not a public procurement in the sense of Directive 2014/24/EU.
What it takes to qualify
Worth a closer look
- The tender is not a public procurement, but a publication for transparency in contract conclusion.
- The exact submission mode and envelope structure are not specified.
- The tender fee and EMD details are not mentioned.
Experience
- At least 1 similar work — Experience as a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) under § 4 Abs. 18 AMG.
- Being a pharmaceutical entrepreneur with a seat in the AMG area, EU, or EEA.
Certifications and registrations
Pharmazeutischer Unternehmer statusMust be a pharmaceutical entrepreneur as defined by § 4 Abs. 18 AMG.
GST registration (optional)Not mentioned in the provided text.
Policy conditions
No reservation, preference or local-content restriction.
Documents to submit
- VertragsunterlagenContract documents must be submitted to AOK Niedersachsen.